Repositioning metformin for cancer prevention and treatment

Trends in Endocrinology and Metabolism

Volumn 24, Issue 9, 2013, Pages 469-480

  Quinn, Brendan J ^a   Kitagawa, Hiroshi ^a   Memmott, Regan M ^a   Gills, Joell J ^a   Dennis, Phillip A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AMPK; Cancer; Chemoprevention; Diabetes; Metformin

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BIGUANIDE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE BETA; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCAGON; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LIPID; LIVER KINASE B1; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; OCTAMER TRANSCRIPTION FACTOR 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; SMALL INTERFERING RNA; SOMATOMEDIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TUBERIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIDIABETIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER CELL; CANCER INCIDENCE; CANCER PATIENT; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER THERAPY; CELL CYCLE ARREST; CELL METABOLISM; CELL PROLIFERATION; CELL RESPIRATION; CELL STRESS; CLINICAL TRIAL (TOPIC); COLON CANCER; DIABETES MELLITUS; DIABETIC PATIENT; DIET; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TRANSPORT; ENDOMETRIUM CANCER; ENZYME ACTIVITY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCOLYSIS; HEREDITY; HUMAN; HYPERINSULINEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPOGENESIS; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LUNG CANCER; MAXIMUM PLASMA CONCENTRATION; MEDIATOR; META ANALYSIS; MITOCHONDRION; NEOPLASM; NONHUMAN; OBESITY; OVARY CANCER; OVARY POLYCYSTIC DISEASE; OVERALL SURVIVAL; PANCREAS CANCER; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEOMICS; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STEADY STATE; TUMOR SUPPRESSOR GENE;

AMPK; CANCER; CHEMOPREVENTION; DIABETES; METFORMIN;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS;

EID: 84883165443     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2013.05.004     Document Type: Review

References (107)

1. Inzucchi S.E., et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N. Engl. J. Med. 1998, 338:867-872.
2. Musi N., et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002, 51:2074-2081.
3. Stumvoll M., et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 1995, 333:550-554.
4. Bailey C.J., Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care 1989, 12:553-564.
5. Kwong S.C., Brubacher J. Phenformin and lactic acidosis: a case report and review. J. Emerg. Med. 1998, 16:881-886.
6. Decensi A., et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev. Res. (Phila.) 2010, 3:1451-1461.
7. Evans J.M., et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330:1304-1305.
8. Giovannucci E., et al. Diabetes and cancer: a consensus report. CA Cancer J. Clin. 2010, 60:207-221.
9. LeRoith D., et al. Insulin-like growth factors and cancer. Ann. Intern. Med. 1995, 122:54-59.
10. Pollak M. Energy metabolism, cancer risk, and cancer prevention. Recent Results Cancer Res. 2009, 181:51-54.
11. Sandhu M.S., et al. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J. Natl. Cancer Inst. 2002, 94:972-980.
12. Chan J.M., et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J. Natl. Cancer Inst. 2002, 94:1099-1106.
13. Vella V., et al. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J. Clin. Endocrinol. Metab. 2002, 87:245-254.
14. Cheng I., et al. Type 2 diabetes risk variants and colorectal cancer risk: the Multiethnic Cohort and PAGE studies. Gut 2011, 60:1703-1711.
15. Sainz J., et al. Effect of type 2 diabetes predisposing genetic variants on colorectal cancer risk. J. Clin. Endocrinol. Metab. 2012, 97:E845-E851.
16. Machiela M.J., et al. Association of type 2 diabetes susceptibility variants with advanced prostate cancer risk in the Breast and Prostate Cancer Cohort Consortium. Am. J. Epidemiol. 2012, 176:1121-1129.
17. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
18. Noto H., et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE 2012, 7:e33411.
19. El-Mir M.Y., et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 2000, 275:223-228.
20. Owen M.R., et al. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 2000, 348:607-614.
21. Zhou G., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001, 108:1167-1174.
22. Hardie D.G., et al. AMP-activated protein kinase: a target for drugs both ancient and modern. Chem. Biol. 2012, 19:1222-1236.
23. Mihaylova M.M., Shaw R.J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 2011, 13:1016-1023.
24. Hardie D.G., et al. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 2012, 13:251-262.
25. Hardie D.G., et al. AMP-activated protein kinase: also regulated by ADP?. Trends Biochem. Sci. 2011, 36:470-477.
26. Hawley S.A., et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2003, 2:28.
27. Woods A., et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 2003, 13:2004-2008.
28. 2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metabo. 2005, 2:21-33.
29. Shaw R.J., et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005, 310:1642-1646.
30. Li Y., et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 2011, 13:376-388.
31. + metabolism and SIRT1 activity. Nature 2009, 458:1056-1060.
32. Canto C., Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol. 2009, 20:98-105.
33. Caton P.W., et al. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J. Endocrinol. 2010, 205:97-106.
34. Shaw R.J., et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:3329-3335.
35. Algire C., et al. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 2011, 30:1174-1182.
36. Shackelford D.B., et al. LKB1 Inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013, 23:143-158.
37. Chiang G.G., Abraham R.T. Targeting the mTOR signaling network in cancer. Trends Mol. Med. 2007, 13:433-442.
38. Inoki K., et al. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
39. Gwinn D.M., et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 2008, 30:214-226.
40. Dowling R.J., et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007, 67:10804-10812.
41. Zakikhani M., et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006, 66:10269-10273.
42. Shaw R.J., et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004, 6:91-99.
43. Huang X., et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem. J. 2008, 412:211-221.
44. Buzzai M., et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007, 67:6745-6752.
45. Jones R.G., et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 2005, 18:283-293.
46. Shackelford D.B., Shaw R.J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 2009, 9:563-575.
47. Foretz M., et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 2010, 120:2355-2369.
48. Miller R.A., Birnbaum M.J. An energetic tale of AMPK-independent effects of metformin. J. Clin. Invest. 2010, 120:2267-2270.
49. Miller R.A., et al. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013, 494:256-260.
50. Kalender A., et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010, 11:390-401.
51. Vazquez-Martin A., et al. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 2009, 8:88-96.
52. Memmott R.M., et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev. Res. (Phila.) 2010, 3:1066-1076.
53. Ben Sahra I., et al. Metformin, independent of AMPK, induces mTOR inhibition and cell cycle arrest through REDD1. Cancer Res. 2011, 71:4366-4372.
54. Bonnefont-Rousselot D., et al. An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress. Metabolism 2003, 52:586-589.
55. Algire C., et al. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev. Res. (Phila.) 2012, 4:536-543.
56. Ben Sahra I., et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008, 27:3576-3586.
57. Dunn C.J., Peters D.H. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995, 49:721-749.
58. Graham G.G., et al. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 2011, 50:81-98.
59. Oliveras-Ferraros C., et al. Pharmacological mimicking of caloric restriction elicits epigenetic reprogramming of differentiated cells to stem-like self-renewal states. Rejuvenation Res. 2010, 13:519-526.
60. Anisimov V.N. Metformin for aging and cancer prevention. Aging (Albany NY) 2010, 2:760-774.
61. Zhang L., et al. Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol. 1997, 51:913-921.
62. Wang D.S., et al. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther. 2002, 302:510-515.
63. Shu Y., et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 2007, 117:1422-1431.
64. Chen Y., et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet. Genomics 2009, 19:497-504.
65. Kimura N., et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab. Pharmacokinet. 2005, 20:379-386.
66. +-organic cation antiporters. Biochem. Pharmacol. 2007, 74:359-371.
67. Stocker S.L., et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin. Pharmacol. Ther. 2013, 93:186-194.
68. Caballero A.E., et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J. Clin. Endocrinol. Metab. 2004, 89:3943-3948.
69. Morin-Papunen L., et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2003, 88:4649-4654.
70. Takemura Y., et al. Metformin suppresses interleukin (IL)-1beta-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells. J. Clin. Endocrinol. Metab. 2007, 92:3213-3218.
71. Isoda K., et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler. Thromb. Vasc. Biol. 2006, 26:611-617.
72. Chakraborty A., et al. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res. Clin. Pract. 2011, 93:56-62.
73. Ersoy C., et al. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res. Clin. Pract. 2008, 81:56-60.
74. Iliopoulos D., et al. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2011, 9:3196-3201.
75. Palomba S., et al. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr. Rev. 2009, 30:1-50.
76. Baillargeon J.P., et al. Insulin sensitizers for polycystic ovary syndrome. Clin. Obstet. Gynecol. 2003, 46:325-340.
77. Lord J.M., et al. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003, 327:951-953.
78. Chittenden B.G., et al. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod. Biomed. Online 2009, 19:398-405.
79. Mu N., et al. Insulin resistance: a significant risk factor of endometrial cancer. Gynecol. Oncol. 2012, 125:751-757.
80. Friedenreich C.M., et al. Case-control study of markers of insulin resistance and endometrial cancer risk. Endocr. Relat. Cancer 2012, 19:785-792.
81. Campagnoli C., et al. Life-style and metformin for the prevention of endometrial pathology in postmenopausal women. Gynecol. Endocrinol. 2013, 29:119-124.
82. Pagano G., et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002, 35:367-372.
83. Bugianesi E., et al. Insulin resistance in nonalcoholic fatty liver disease. Curr. Pharm. Des. 2010, 16:1941-1951.
84. Hui J.M., et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003, 125:1695-1704.
85. Shintani Y., et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004, 126:840-848.
86. Ascha M.S., et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010, 51:1972-1978.
87. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
88. Loomba R., et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2009, 29:172-182.
89. Haukeland J.W., et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand. J. Gastroenterol. 2009, 44:853-860.
90. Chalasani N., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023.
91. Romero-Gomez M., et al. Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009, 50:1702-1708.
92. Harrison S.A., et al. Insulin resistance in chronic hepatitis C: the search for effective drug treatment continues. Expert Rev. Gastroenterol. Hepatol. 2012, 6:401-403.
93. Nkontchou G., et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J. Clin. Endocrinol. Metab. 2011, 96:2601-2608.
94. Dilman V.M. Age-associated elevation of hypothalamic threshold to feedback control, and its role in development, ageing, and disease. Lancet 1971, 297:1211-1219.
95. Dilman V.M., et al. Preliminary evidence on metabolic rehabilitation of cancer patients. Arch. Geschwulstforsch. 1988, 58:175-183.
96. Dilman V.M. Pathogenetic approaches to prevention of age-associated increase of cancer incidence. Ann. N. Y. Acad. Sci. 1991, 621:385-400.
97. Goodwin P.J., et al. Insulin-lowering effects of metformin in women with early breast cancer. Clin. Breast Cancer 2008, 8:501-505.
98. Campagnoli C., et al. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. Clin. Breast Cancer 2012, 12:175-182.
99. Hadad S., et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res. Treat. 2011, 128:783-794.
100. Jiralerspong S., et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol. 2009, 27:3297-3302.
101. Nobes J.P., et al. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int. 2012, 109:1495-1502.
102. Rezzonico J., et al. Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metab. Syndr. Relat. Disord. 2011, 9:69-75.
103. Hosono K., et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev. Res. (Phila.) 2010, 3:1077-1083.
104. Tan B.X., et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer 2011, 117:5103-5111.
105. He X.X., et al. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann. Oncol. 2011, 22:2640-2645.
106. Goodwin P.J., et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res. Treat. 2011, 126:215-220.
107. Martin M.J., et al. Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2012, 2:344-355.